Endothelial glycocalyx as potential diagnostic and therapeutic target in cardiovascular disease

Current Opinion in Lipidology

Volumn 20, Issue 1, 2009, Pages 57-62

  Broekhuizen, Lysette N ^a   Mooij, Hans L ^a   Kastelein, John J P ^a   Stroes, Erik S G ^a   Vink, Hans ^a,c   Nieuwdorp, Max ^a,b  

^a Department of Vascular Medicine ^*  (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; GLYCOSAMINOGLYCAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROTEOGLYCAN;

ATHEROGENESIS; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; BLOOD VESSEL PERMEABILITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIAGNOSTIC VALUE; DISEASE MARKER; ELECTRON MICROSCOPY; GLYCOCALYX; HOMEOSTASIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; INFLAMMATION; INFLAMMATORY DISEASE; INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NOTE; PRIORITY JOURNAL; SPECTROSCOPY; VASCULAR ENDOTHELIUM;

ANIMALS; CARDIOVASCULAR DISEASES; ENDOTHELIAL CELLS; GLYCOCALYX; HOMEOSTASIS; HUMANS; RISK;

EID: 58849122773     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOL.0b013e328321b587     Document Type: Note

References (46)

1. Vink H, Duling BR. Identification of distinct luminal domains for macromolecules, erythrocytes, and leukocytes within mammalian capillaries. Circ Res 1996; 79:581-589.
2. Potter DR, Damiano ER. The hydrodynamically relevant endothelial cell glycocalyx observed in vivo is absent in vitro. Circ Res 2008; 102:770-776. For more information on the importance of the endothelial glycocalyx.
3. van den Berg BM, Vink H, Spaan JA. The endothelial glycocalyx protects against myocardial edema. Circ Res 2003; 92:592-594.
4. van den Berg BM, Nieuwdorp M, Stroes ES, Vink H. Glycocalyx and endothelial (dys) function: from mice to men. Pharmacol Rep 2006; 58 (Suppl):75-80.
5. van Haaren PM, VanBavel E, Vink H, Spaan JA. Localization of the permeability barrier to solutes in isolated arteries by confocal microscopy. Am J Physiol Heart Circ Physiol 2003; 285:H2848-H2856.
6. Van Teeffelen JW, Brands J, Stroes ES, Vink H. Endothelial glycocalyx: sweet shield of blood vessels. Trends Cardiovasc Med 2007; 17:101-105.
7. Gouverneur M, Spaan JAE, Pannekoek H, et al. Fluid shear stress stimulates incorporation of hyaluronan into the endothelial cell glycocalyx. Am J Physiol Heart Circ Physiol 2006; 290:H458-H462.
8. Freeze HH. Genetic defects in the human glycome. Nat Rev Genet 2006; 7:537-551.
9. Bishop JR, Schuksz M, Esko JD. Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature 2007; 446:1030-1037. This study describes the importance of heparin sulphate proteoglycans (HSPGs) in various systems.
10. Presto J, Thuveson M, Carlsson P, et al. Heparan sulfate biosynthesis enzymes EXT1 and EXT2 affect NDST1 expression and heparan sulfate sulfation. Proc Natl Acad Sci U S A 2008; 105:4751 -4756.
11. Marechal X, Favory R, Joulin O, et al. Endothelial glycocalyx damage during endotoxemia coincides with microcirculatory dysfunction and vascular oxidative stress. Shock 2008; 29:572-576. This study shows that endotoxin administration in rats induces dysfunction of the microcirculation accompanied by glycocalyx degradation.
12. Meuwese MC, Broekhuizen LN, Heeneman S, et al. Effect of chronic hyaluronidase infusion on kidney function and atherosclerosis progression in ApoE-deficient mice [abstract]. FASEB J 2008; 22:924.20.
13. Nieuwdorp M, van Haeften TW, Gouverneur MC, et al. Loss of endothelial glycocalyx during acute hyperglycemia coincides with endothelial dysfunction and coagulation activation in vivo. Diabetes 2006; 55:480-486.
14. Nieuwdorp M, Mooij HL, Kroon J, et al. Endothelial glycocalyx damage coincides with microalbuminuria in type 1 diabetes. Diabetes 2006; 55:1127-1132.
15. Nieuwdorp M, Holleman F, de Groot E, et al. Perturbation of hyaluronan metabolism predisposes patients with type 1 diabetes mellitus to atherosclerosis. Diabetologia 2007; 50:1288-1293.
16. Nieuwdorp M, Meuwese MC, Mooij HL, et al. Tumor necrosis factor-alpha inhibition protects against endotoxin-induced endothelial glycocalyx perturbation. Atherosclerosis 2008 [Epub ahead of print].
17. VanTeeffelen JW, Brands J, Jansen C, et al. Heparin impairs glycocalyx barrier properties and attenuates shear dependent vasodilation in mice. Hypertension 2007; 50:261 -267.
18. Bruegger D, Rehm M, Jacob M, et al. Exogenous nitric oxide requires an endothelial glycocalyx to prevent postischemic coronary vascular leak in guinea pig hearts. Crit Care 2008; 12:R73.
19. Noble Ml, Drake-Holland AJ, Vink H. Hypothesis: arterial glycocalyx dysfunction is the first step in the atherothrombotic process. QJM 2008; 101:513-518.
20. Pahakis MY, Kosky JR, Dull RO, Tarbell JM. The role of endothelial glycocalyx components in mechanotransduction of fluid shear stress. Biochem Biophys Res Commun 2007; 355:228-233.
21. Proudfoot AE, Handel TM, Johnson Z, et al. Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines. Proc Natl Acad Sci U S A 2003; 100:1885-1890.
22. Varki AP, Baum LG, Bellis SL, et al. Working group report: the roles of glycans in hemostasis, inflammation and vascular biology. Glycobiology 2008; 18:747-749.
23. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 2006; 6:508-519.
24. Henry CB, Duling BR. TNF-alpha increases entry of macromolecules into luminal endothelial cell glycocalyx. Am J Physiol Heart Circ Physiol 2000; 279:H2815-H2823.
25. Lortat-Jacob H, Grosdidier A, Imberty A. Structural diversity of heparan sulfate binding domains in chemokines. Proc Natl Acad Sci U S A 2002; 99:1229-1234.
26. Mulivor AW, Lipowsky HH. Role of glycocalyx in leukocyte-endothelial cell adhesion. Am J Physiol Heart Circ Physiol 2002; 283:H1282-H1 291.
27. Varki A. Sialic acids in human health and disease. Trends Mol Med 2008; 14:351 -360.
28. Gonzalez-Gay MA, Gonzalez-Juanatey C, Martin J. Rheumatoid arthritis: a disease associated with accelerated atherogenesis. Semin Arthritis Rheum 2005; 35:8-17.
29. Gonzalez-Juanatey C, Llorca J, Garcia-Porrua C, et al. Effect of antitumor necrosis factor alpha therapy on the progression of subclinical atherosclerosis in severe rheumatoid arthritis. Arthritis Rheum 2006; 55:150-153.
30. Sattar N, Mclnnes IB. Vascular comorbidity in rheumatoid arthritis: potential mechanisms and solutions. Curr Opin Rheumatol 2005; 17:286-292.
31. Ikonomidis I, Lekakis JP, Nikolaou M, et al. Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis. Circulation 2008; 117:2662-2669.
32. Bosello S, Santoliquido A, Zoli A, et al. TNF-alpha blockade induces a reversible but transient effect on endothelial dysfunction in patients with long-standing severe rheumatoid arthritis. Clin Rheumatol 2008; 27:833-839.
33. Hurlimann D, Forster A, Noll G, et al. Antitumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 2002; 106:2184-2187.
34. Gonzalez-Juanatey C, Testa A, Garcia-Castelo A, et al. Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with antitumor necrosis factor alpha antibody. Arthritis Rheum 2004; 51:447-450.
35. Jeansson M, Haraldsson B. Glomerular size and charge selectivity in the mouse after exposure to glucosaminoglycan-degrading enzymes. J Am Soc Nephrol 2003; 14:1756-1765.
36. Jeansson M, Haraldsson B. Morphological and functional evidence for an important role of the endothelial cell glycocalyx in the glomerular barrier. Am J Physiol Renal Physiol 2006; 290:F111-F116.
37. Singh A, Satchell SC, Neal CR, et al. Glomerular endothelial glycocalyx constitutes a barrier to protein permeability. J Am Soc Nephrol 2007; 18:2885-2893.
38. van den Berg BM, Spaan JAE, Vink H. Impaired glycocalyx barrier properties contribute to enhanced intimal low-density lipoprotein accumulation at the carotid artery bifurcation in mice. Eur J Physiol 2008 [Epub ahead of print]. This study describes the essential barrier function of the endothelial glycocalyx by showing that cholesterol accumulation is most profound in vascular areas with an impaired glycocalyx.
39. van den Berg BM, Spaan JA, Rolf TM, Vink H. Atherogenic region and diet diminish glycocalyx dimension and increase intima-to-media ratios at murine carotid artery bifurcation. Am J Physiol Heart Circ Physiol 2006; 290:H915-H920.
40. Fuki IV, Kuhn KM, Lomazov IR, et al. The syndecan family of proteoglycans. Novel receptors mediating internalization of atherogenic lipoproteins in vitro. J Clin Invest 1997; 100:1611-1622.
41. Meuwese MC, Mooij HL, Nieuwdorp M, et al. Partial recovery of the endothelial glycocalyx upon rosuvastatin therapy in patients with heterozygous familial hypercholesterolemia. J Lipid Res 2008 [Epub ahead of print].
42. Nieuwdorp M, Meuwese MC, Mooij HL, et al. Measuring endothelial glycocalyx dimensions in humans: a potential novel tool to monitor vascular vulnerability. J Appl Physiol 2008; 104:845-852. This study provides additional information on the OPS technique and shows that glycocalyx dimensions measured by this method are reproducible in humans.
43. Pilobello KT, Mahal LK. Lectin microarrays for glycoprotein analysis. Methods Mol Biol 2007; 385:193-203.
44. Rehm M, Bruegger D, Christ F, et al. Shedding of the endothelial glycocalyx in patients undergoing major vascular surgery with global and regional ischemia. Circulation 2007; 116:1896-1906. This study describes that there is an increase in glycocalyx degradation products after perioperative ischemia/reperfusion and that these products can be measured in plasma.
45. Rubio-Gayosso I, Platts SH, Duling BR. Reactive oxygen species mediate modification of glycocalyx during ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 2006; 290:H2247-H2256.
46. Morrow DA, de Lemos JA. Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation 2007; 115:949-952.